Cargando…
Autophagy Inhibition in BRAF-Driven Cancers
SIMPLE SUMMARY: BRAF is a protein kinase that is frequently mutationally activated in cancer. Mutant BRAF can be pharmacologically inhibited, which in combination with blockade of its direct effector, MEK1/2, is an FDA-approved therapeutic strategy for several BRAF-mutated cancer patients, such as m...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306561/ https://www.ncbi.nlm.nih.gov/pubmed/34298710 http://dx.doi.org/10.3390/cancers13143498 |